NCT01625520View on ClinicalTrials.gov

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2016

Conditions
Medullary Thyroid Cancer
Interventions
DRUG

SOM230 alone or in combination with RAD001.

SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.

Trial Locations (1)

80131

"Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples", Naples

All Listed Sponsors
lead

Federico II University

OTHER

NCT01625520 - SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter